Author Response: Homeostatic Regulation of Perisynaptic Matrix Metalloproteinase 9 (MMP9) Activity in the Amblyopic Visual Cortex
Sachiko Murase,Dan Winkowski,Liu Ji,Patrick O. Kanold,Elizabeth Quinlan
DOI: https://doi.org/10.7554/elife.52503.sa2
2019-01-01
Abstract:Article Figures and data Abstract Introduction Results Discussion Materials and methods Data availability References Decision letter Author response Article and author information Metrics Abstract Dark exposure (DE) followed by light reintroduction (LRx) reactivates robust synaptic plasticity in adult mouse primary visual cortex (V1), which allows subsequent recovery from amblyopia. Previously we showed that perisynaptic proteolysis by MMP9 mediates the enhancement of plasticity by LRx in binocular adult mice (Murase et al., 2017). However, it was unknown if a visual system compromised by amblyopia could engage this pathway. Here we show that LRx to adult amblyopic mice induces perisynaptic MMP2/9 activity and extracellular matrix (ECM) degradation in deprived and non-deprived V1. Indeed, LRx restricted to the amblyopic eye is sufficient to induce robust MMP2/9 activity at thalamo-cortical synapses and ECM degradation in deprived V1. Two-photon live imaging demonstrates that the history of visual experience regulates MMP2/9 activity in V1, and that DE lowers the threshold for the proteinase activation. The homeostatic reduction of the MMP2/9 activation threshold by DE enables visual input from the amblyopic pathway to trigger robust perisynaptic proteolysis. Introduction An imbalance in the quality of visual inputs between the two eyes during development induces amblyopia, a developmental disorder affecting up to 4% of the world’s population (Levi et al., 2015). In animal models, prolonged monocular deprivation induces severe amblyopia, characterized by a significant decrease in the strength and selectivity of neuronal responses in the deprived visual cortex (Fong et al., 2016; Harwerth et al., 1983; Montey et al., 2013) and a significant loss of spatial acuity through the deprived eye (Harwerth et al., 1983; Liao et al., 2011; Montey et al., 2013). In rats, spatial acuity in the deprived eye is undetectable following chronic monocular deprivation (cMD) initiated at eye opening (Eaton et al., 2016). Additionally, following prolonged monocular deprivation, neurons in the dorsal lateral geniculate nucleus (dLGN) that project to deprived binocular visual cortex have lower metabolism (Kennedy et al., 1981) and smaller somata (Duffy et al., 2018). cMD also significantly decreases the density of dendritic spines on pyramidal neurons in deprived binocular primary visual cortex (V1b) (Montey and Quinlan, 2011) and induces a 60% decrease in the thalamic component of the visually evoked potential (VEP, [Montey and Quinlan, 2011]). The loss of synaptic plasticity in the primary visual cortex with age is thought to significantly impede the reversal of amblyopic deficits (Tailor et al., 2017). Strong evidence demonstrates that developmental changes in the induction of synaptic plasticity in V1 are regulated by the maturation of fast-spiking basket interneurons (INs) that express the Ca2+ binding protein parvalbumin (PV) (Gu et al., 2016; Gu et al., 2013; Morishita et al., 2015; Stephany et al., 2016; Sun et al., 2016). PV+ INs mediate the perisomatic inhibition of pyramidal neurons, thereby exerting powerful control of neuronal excitability and spike-timing dependent synaptic plasticity. Developmental changes in synaptic plasticity are also associated with the composition and density of the ECM, comprised of chondroitin sulfate proteoglycans (CSPGs) and hyaluronic acid, linked via cartilage link protein and tenascins (Carulli et al., 2010; Celio and Chiquet-Ehrismann, 1993; Morawski et al., 2014). Importantly, ECM molecules condense into perineuronal nets (PNNs) around a subset of PV+ INs, limiting their structural and functional plasticity by imposing a physical constraint and providing binding sites for molecules that inhibit neurite outgrowth (Dickendesher et al., 2012; Frantz et al., 2016; Stephany et al., 2016; Vo et al., 2013). PNNs also accumulate molecules that regulate PV+ IN excitability and maturation (Beurdeley et al., 2012; Chang et al., 2010; Hou et al., 2017). Manipulations that reduce the integrity of the ECM/PNNs have been repeatedly shown to enhance plasticity in V1 and elsewhere. Treatment of adult V1 with the bacterial enzyme chondroitinase ABC (ChABC), which cleaves the CS side chains from the CSPGs, reactivates robust plasticity in rats (Pizzorusso et al., 2006; Pizzorusso et al., 2002). However, recovery from MD is incomplete in cats that receive ChABC following eye opening (Vorobyov et al., 2013). Enhancement of synaptic plasticity following ChABC treatment has also been demonstrated in many other brain regions (Carstens et al., 2016; Carstens and Dudek, 2019; Gogolla et al., 2009; Kochlamazashvili et al., 2010; Romberg et al., 2013; Zhao et al., 2007). Genetic ablation of cartilage link protein (Crtl1/Halpn1), which prevents the condensation of ECM molecules into PNNs, prevents the closure of the critical period for ocular dominance plasticity (Carulli et al., 2010). Dark rearing from birth produces a parallel delay in the maturation of ECM/PNNs and the closure of the critical period (Lander et al., 1997; Mower, 1991; Pizzorusso et al., 2002). However, robust juvenile-like synaptic plasticity can be restored in adults by complete visual deprivation through DE followed by LRx (He et al., 2006). Our previous work demonstrated DE/LRx induces an increase in perisynaptic activity of MMP9 and subsequent proteolysis of extracellular targets in binocular adult mice (Murase et al., 2017). The proteinase activity induced by LRx is perisynaptic and enriched at thalamo-cortical synapses.Importantly, the reactivation of structural and functional plasticity by DE/LRx is inhibited by pharmacological blockade and genetic ablation of MMP9. Although Mmp9-/- mice are resistant to enhancement of plasticity by DE/LRx, treatment with hyaluronidase activates structural and functional plasticity in adults. In adult rats rendered severely amblyopic by cMD from eye opening to adulthood, DE followed by reverse occlusion enables recovery of the VEP amplitude and dendritic spine density in deprived V1b (He et al., 2007; Montey and Quinlan, 2011). Subsequent visual training promotes a full recovery of visual acuity in the deprived eye (Eaton et al., 2016). A similar reactivation of plasticity by DE has been reported in several species (Duffy and Mitchell, 2013; Stodieck et al., 2014). However, it is not known if the reactivation of plasticity in the amblyopic cortex is dependent on MMP9 activity or if this pathway can be engaged by the severely compromised visual system of an amblyope. Here we use a biomarker that reports the activity of MMP2/9 in vivo to examine the effects of DE/LRx on extracellular proteolysis in amblyopic mice. We show that DE lowers the threshold for activation of MMP2/9 by light, such that LRx to the deprived eye is sufficient to induce perisynaptic proteolysis at thalamo-cortical synapses and ECM degradation in deprived visual cortex. Results LRx activates perisynaptic MMP2/9 activity at thalamo-cortical synapses in deprived and non-deprived V1b To test the hypothesis that LRx to amblyopic mice induces an increase in perisynaptic proteinase activity in V1b, we employed an exogenous MMP2/9 substrate in which fluorescence emission is quenched by intramolecular FRET when the substrate is intact (DQ gelatin; D12054; excitation/emission = 495/519 nm). Proteolysis of the substrate interrupts FRET and allows fluorescence emission, thereby reporting enzymatic activity. MMP9 has highly overlapping substrate specificity with MMP2 (Szklarczyk et al., 2002), and therefore the exogenous substrate(hereafter called biomarker) reports the activity of both metalloproteinases. However, our previous work demonstrated that LRx does not induce an increase in biomarker expression in Mmp9-/- mice (Murase et al., 2017). The MMP2/9 biomarker was delivered to V1b in vivo 24 hr prior to the onset of LRx (2 mg/ml, i.c. via cannula implanted 3 weeks prior to injection; 4 μl at 100 nl/min) and fluorescence emissionwas quantified in layer 4 of V1b 4 hr after LRx. Ex vivo imaging revealed punctate MMP2/9 activity in the deprived and non-deprived V1b (Figure 1A) that was similar in size, density and fluorescence intensity as previously described in binocular adult mice (Murase et al., 2017). No differences were observed following cMD between deprived and non-deprived V1b biomarker puncta size (deprived: 0.77 ± 0.06 μm2, non-deprived: 0.83 ± 0.06 μm2), density (deprived: 22.9 ± 2.5 puncta/0.01 mm2, non-deprived: 28.9 ± 6.6 puncta/0.01 mm2) or intensity (deprived: 42.2 ± 2.8 pixel, non-deprived: 40.6 ± 2.8 pixel, n = 6 for deprived, n = 5 for non-deprived, Figure 1A). However, LRx induced a significant and parallel increase in MMP2/9 biomarker puncta density (deprived: 67.0 ± 8.0 puncta/0.01 mm2, non-deprived: 70.2 ± 14.7 puncta/0.01 mm2) and puncta intensity (deprived: 55.6 ± 2.6 pixel, non-deprived: 54.6 ± 2.8 pixel) in deprived and non-deprived V1b, with no difference in puncta size (deprived: 0.88 ± 0.06 μm2, non-deprived: 0.86 ± 0.06 μm2, n = 6 subjects, One-way ANOVAs, density F(3, 19)=6.7, p=0.003; intensity F(3, 19)=8.4, p=0.0009; size F(3, 19)=0.52, p=0.67; *p<0.05, Tukey-Kramer post hoc test; Figure 1A). Figure 1 Download asset Open asset Parallel increase in MMP2/9 activity following LRx at thalamo-cortical synapses in deprived and non-deprived V1b. (A) Top: Experimental timeline. Subjects received cMD from eye opening (postnatal day 14, (P14) until adulthood (>P90). 10 days of DE was followed by 4 hr of LRx. MMP2/9 biomarker (4 μl of 2 mg/ml Dye-quenched gelatin) was delivered i.c. 24 hr prior to 4 hr of LRx. Middle left: Coronal section with DAPI nuclear staining. Layer 4 of binocular region of V1 indicated by red box. Middle right: representative images of MMP2/9 biomarker fluorescence in deprived (dep) and non-deprived (non) V1b in cMD (left) and cMD+LRx subjects (LRx, right). Bottom: Quantification of biomarker puncta reveals no change in puncta size (left), but a parallel and significant increase in puncta density (middle) and fluorescent intensity (right) in dep and non V1b following LRx. One-way ANOVAs, size F(3, 19)=0.52, p=0.67; density F(3, 19)=6.7, p=0.003; intensity F(3, 19)=8.4, p=0.0009; n = 6, 5, 6, 6 subjects for cMD dep, cMD non, LRx dep, LRx non, respectively; *p<0.05, Tukey-Kramer post hoc test. (B) Representative images of MMP2/9 biomarker fluorescence (MMP; green) and marker for thalamic axons (VG2; magenta) in deprived visual cortex in cMD and cMD+LRx subjects. A parallel and significant increase in colocalization of biomarker puncta with VGluT2 following LRx in dep and non V1b. One-way ANOVA, F(3, 19)=9.5, p=0.0005; n = 6, 5, 6, 6 subjects for cMD dep, cMD non, LRx dep, LRx non, respectively; *p<0.05, Tukey-Kramer post hoc test. Co-localization with VGluT2 is lost following 2 μm shift of biomarker image (shift). (C) Representative images of MMP2/9 biomarker (green), VGluT2 (magenta) and parvalbumin fluorescence (PV; blue) in deprived and non-deprived cMD and cMD+LRx subjects. Significant increase in co-localization of biomarker puncta with VGluT2 at PV+ and PV-locations of dep and non V1b following LRx. One-way ANOVAs, PV+ F(3, 12)=17.33, p=0.00012; PV- F(3, 12)=56.17, p<0.0001; n = 4, 4, 4, 4 subjects for cMD dep, cMD non, LRx dep, LRx non, respectively; *p<0.05, Tukey-Kramer post hoc test. (D) Left: Representative immunoblots for active MMP9 (95 kDa), and β-actin from dep and non V1b. MMP9 level is normalized to β-actin and reported as % of cMD non. Right: Quantification of immunoblots reveals a parallel and significant increase in active MMP9 in dep and non V1b following 2 hr of LRx. One-way ANOVA, F(3, 26)=5.6, p=0.004; n = 7, 7, 8, 8 subjects for cMD dep, cMD non, LRx dep, LRx non, respectively: *p<0.05, Tukey-Kramer post hoc test. Figure 1—source data 1 Source data for Figure 1. https://cdn.elifesciences.org/articles/52503/elife-52503-fig1-data1-v2.xlsx Download elife-52503-fig1-data1-v2.xlsx Biomarker puncta co-localization with thalamic axons, labelled with anti-vesicular glutamate transporter 2 (VGluT2) antibody, was low in deprived and non-deprived V1b of amblyopes (~30%), as previously described in binocular adults. LRx induced a significant and parallel increase in biomarker co-localization with VGluT2 in deprived and non-deprived V1b, indicating an increase in MMP2/9 activity at thalamo-cortical synapses (deprived: 161 ± 6%, non-deprived: 199 ± 17%, n = 6, 5, 6, 6 subjects for cMD dep, cMD non, LRx dep, LRx non, respectively; One-way ANOVA, F(3, 19)=9.5, p=0.0005; *p<0.05, Tukey-Kramer post hoc test; Figure 1B). To control for false positives, we re-analyzed the co-localization following a 2 μm shift of the biomarker image relative to VGlut2. Following this manipulation we observe low co-localization of the two fluorescent signals that was unchanged by LRx (cMD dep: 7.8 ± 3.0%, cMD non-dep: 5.3 ± 2.7%, LRx dep: 6.9 ± 3.0%, LRx non-dep: 8.4 ± 3.0%) which differs significantly from co-localization of the 2 images (cMD dep: p=0.0029, cMD non-dep: p=0.036, LRx dep: p=1.5×10−5, LRx non-dep: p=9.5×10−6, paired Student’s T-Test, Figure 1B). The LRx-induced increase in co-localization of biomarker and VGluT2 was observed at PV+ neuronal somata and in PV- locations, suggesting widespread activation of perisynaptic MMP2/9 (dep: 625.3 ± 50.1%, non: 484.1 ± 35.2% for PV+, dep: 361.7 ± 34.5%, non: 537.1 ± 85.4% for PV-, n = 4 subjects; One-way ANOVA, PV+ F(3, 12)=17.33, p=0.00012; PV- F(3, 12)=56.17, p<0.0001; *p<0.05, Tukey-Kramer post hoc test; Figure 1C). To ask if the increase in MMP biomarker fluorescence reflects an increase in the activation of MMP9, we performed quantitative western blots for the active MMP9 isoform (95 kDa), which can be distinguished from inactive pro-MMP9 (105 kDa, [Szklarczyk et al., 2002]). Quantitative immunoblot analysis showed that DE followed by 2 hr of LRx significantly increased the concentration of active MMP9 in parallel in deprived and non-deprived V1b of adult cMD mice (% of cMD dep: 133.04 ± 9.1%; non: 131.37 ± 8.9%; n = 7, eight subjects for cMD and LRx, respectively; One-way ANOVA, F(3, 26)=5.6, p=0.004; *p<0.05, Tukey-Kramer post hoc test; Figure 1D). LRx induces a parallel degradation of ECM in deprived and non-deprived V1b MMP9 has several extracellular targets, including aggrecan (Agg) the predominant CSPG in the ECM of the adult mammalian cortex (Mercuri et al., 2000). To test the hypothesis that LRx to the amblyopic cortex induces ECM degradation, we examined the distribution of Wisteria floribunda agglutinin (WFA), a plant lectin that binds to the CS side chains of CSPGs, combined with immunoreactivity for Agg and PV. Diffuse WFA and Agg fluorescence was observed throughout the depth of the V1b, with a peak between 250–400 μm from the cortical surface. In addition, WFA and Agg fluorescence was concentrated around the perisomatic area of a subset of PV+ INs (Figure 2A and B, WFA and IHC of PV in Figure 2—figure supplement 1). Importantly, the intensity and distribution of WFA and Agg fluorescence were similar between deprived and non-deprived V1b. LRx induced a significant decrease in the intensity of WFA and Agg, but not PV labeling, 250 μm-400 μm from the cortical surface (mean ± SEM; % of cMD, WFA dep 54.3 ± 3.5, non 46.3 ± 3.4, One way ANOVAs, F(3, 26)=32, p<0.0001; Agg dep 62.3 ± 3.1, non 54.3 ± 4.5, F(3, 26)=10, p=0.0001; PV dep 105.0 ± 6.9, non 96.4 ± 4.5; F(3, 26)=0.4, p=0.75; n = 7, 7, 8, 8 subjects for cMD dep, cMD non, LRx dep, LRx non, respectively; *p<0.05, Tukey-Kramer post hoc test; Figure 2C). Line scans of triple-labeled images revealed that the decrease in WFA and Agg staining was observed at PV+ and PV- locations suggesting widespread degradation of ECM upon LRx (% of cMD, WFA PV+ dep 56.3 ± 2.1, non 55.4 ± 2.1; One-way ANOVAs, F(3, 309)=40.3, p<0.0001; WFA PV- dep 69.5 ± 1.9, non 66.8 ± 1.3; F(3, 309)=30.1, p<0.0001; Agg PV+ dep 61.9 ± 1.4, non 60.2 ± 1.4; F(3, 309)=29.4, p<0.0001; Agg PV- dep 77.1 ± 1.2, non 71.0 ± 1.3; F(3, 309)=18.7, p<0.0001; n (subjects, ROIs)=(5, 77 , 5, 73 , 5, 81 , 5, 82), for cMD dep, cMD non, LRx dep, LRx non, respectively; *p<0.05, Tukey-Kramer post hoc test; Figure 2D). Figure 2 with 1 supplement see all Download asset Open asset Parallel decrease in ECM integrity following LRx in deprived and non-deprived V1b. (A) Representative triple labeled fluorescent micrographs of Wisteria floribunda agglutinin (WFA)-FITC staining (cyan), immunostaining for aggrecan (Agg; yellow) and parvalbumin (PV; magenta) in deprived (dep) and non-deprived (non) V1b in cMD (left) and cMD+LRx subjects (LRx, right). Roman numerals indicate cortical layer. WM = white matter. Inset: High magnification images of triple labeled PV+ interneurons (100X). (B) Fluorescence intensity profiles (mean ± SEM) along vertical depth of V1b. cMD dep (dark blue), cMD non (light blue), LRx dep (dark red), LRx non (red). (C) A parallel and significant decrease in WFA and Agg mean fluorescence intensity 250–400 μm from surface in dep and non V1b following LRx. One-way ANOVAs, WFA F(3, 26)=32, p=0.0001; Agg F(3, 26)=10, p=0.0001; PV F(3, 26)=0.4, p=0.75; n = 7, 7, 8, eight subjects for cMD dep, cMD non, LRx dep, LRx non, respectively; *p<0.05, Tukey-Kramer post hoc test. (D) LRx induces a significant decrease in WFA and Agg fluorescence intensity at PV+ and PV-locations in dep and non V1b. One-way ANOVAs, WFA PV+, F(3, 309)=40.3, p<0.0001; WFA PV-, F(3, 309)=30.1, p<0.0001; Agg PV+, F(3, 309)=29.4, p<0.0001; Agg PV-, F(3, 309)=18.7, p<0.0001; n (subjects, ROIs)=(5, 77 , 5, 73 , 5, 81 , 5, 82), for cMD dep, cMD non, LRx dep, LRx non, respectively; *p<0.05, Tukey-Kramer post hoc test. Figure 2—source data 1 Source data for Figure 2. https://cdn.elifesciences.org/articles/52503/elife-52503-fig2-data1-v2.xlsx Download elife-52503-fig2-data1-v2.xlsx LRx to cMD eye is sufficient to activate MMP2/9 at thalamic input to deprived V1 The LRx-induced increase in MMP2/9 activity and degradation of ECM in the deprived V1b could reflect activity of either deprived or non-deprived eye inputs to V1b. To ask if LRx to the amblyopic eye was sufficient to drive an increase in MMP2/9 activity in deprived V1b, LRx was delivered to adult amblyopes with a light-occluding eye patch covering the non-deprived eye. LRx restricted to the amblyopic eye induced an increase in MMP2/9 biomarker density and intensity in layer four in deprived V1b (contralateral to the cMD eye, ipsilateral to eye patch) relative to non-deprived V1b (ipsilateral to the cMD eye, contralateral to eye patch; density: 208.8 ± 23.1% of non, n = 6 subjects, p=0.014; intensity: 161.1 ± 22.9% of non, n = 6 subjects, p=0.046, Student’s T-test), with no change in biomarker puncta size (111.7 ± 14.8% of non, n = 6 subjects, p=0.56, Student’s T-test; Figure 3A). Similarly, LRx restricted to the amblyopic eye induced a significant increase in the co-localization of MMP2/9 biomarker puncta with VGluT2 in deprived relative to non-deprived V1b (dep: 57.8 ± 3.5%; non: 33.4 ± 5.0%, n = 6 subjects, p=0.0026, Student’s T-test; Figure 3B). Co-localization with VGluT2 following a 2 μm shift of the biomarker image was low: dep: 8.0 ± 3.9%; non: 7.0 ± 3.9%, and significantly different from co-localization with the two images correctly registered (dep: p=3.2×10−5; non: p=0.0017, paired Student’s T-test; Figure 3B). Again, the LRx-induced increase in co-localization of MMP2/9 biomarker and VGluT2 was observed at PV+ and PV- locations (PV+: 334 ± 91% of non, n = 4 subjects, p=0.04, PV-: 271 ± 38% of non, n = 4 subjects, p=0.03, Student’s T-test; Figure 3C). Figure 3 Download asset Open asset LRx limited to deprived eye is sufficient to induce perisynaptic MMP2/9 activity at thalamo-cortical synapses in deprived V1b. (A) Top: Experimental timeline. A light-occluding eye patch was attached to the non-deprived eye before DE. Bottom left: Representative images of MMP2/9 biomarker fluorescence in layer 4 of chronically deprived (dep, contralateral to cMD, ipsilateral to eye patch) and non-deprived (non, ipsilateral to cMD, contralateral to eye patch) V1b of LRx subject. Quantification of biomarker puncta reveals a significant increase in density and intensity in dep vs non V1b following LRx to amblyopic eye; n = 6, six subjects for LRx dep, LRx non, respectively; *p<0.05, Student’s T-test. (B) Representative images of MMP2/9 biomarker fluorescence (MMP, green) and VGluT2 immunoreactivity (VG2, magenta) in dep and non V1b of LRx subject. A significant increase in biomarker colocalization with VGluT2 in dep vs non V1b following LRx to amblyopic eye; n = 6, six subjects for LRx dep, LRx non, respectively; *p<0.05, Student’s T-test. Co-localization with VGluT2 is reduced following 2 μm shift of biomarker image (shift). (C) Representative images of MMP2/9 biomarker (green), VGluT2 (magenta) and parvalbumin fluorescence (PV, blue) in dep and non V1b following LRx. A significant increase in co-localization of MMP2/9 biomarker puncta with VGluT2 at PV+ and PV- immunoreactive locations of dep vs non V1b; n = 4; *p<0.05, Student’s T-test. Figure 3—source data 1 Source data for Figure 3. https://cdn.elifesciences.org/articles/52503/elife-52503-fig3-data1-v2.xlsx Download elife-52503-fig3-data1-v2.xlsx LRx to deprived eye is sufficient to induce ECM degradation in deprived V1b To ask if LRx restricted to the amblyopic eye is sufficient to induce ECM degradation in deprived V1b, we again employed a light-occluding patch on the non-deprived eye. LRx to the deprived eye alone induced a decrease in the mean fluorescence intensity of WFA and Agg in layer 4 of deprived V1b (contralateral to cMD eye, ipsilateral to eye patch) relative to non-deprived V1b (ipsilateral to cMD eye, contralateral to eye patch; quantified 250 μm - 400 μm from the cortical surface: WFA: 48.7 ± 7.0% of non, n = 5 subjects, p=0.0009; Agg: 50.2 ± 16.1% of non, n = 5 subjects, p=0.02, Student’s T-test), with PV fluorescence unchanged (83.3 ± 17.7% of non-deprived, n = 5 subjects, p=0.4, Student’s T-test; Figure 4A–C, WFA and IHC of PV in Figure 4—figure supplement 1). Line scans of triple-labeled images revealed that the decrease in WFA and Agg staining was observed at PV+ and PV- locations (% of non: WFA PV+: 40.1 ± 2.4%, WFA PV-38.7 ± 1.0%, Agg PV+: 37.0 ± 1.9%, Agg PV-: 52.4 ± 2.0% of non; all p<0.001, Student’s T-test; n (subjects, ROIs) = (5, 73 , 5, 78), for LRx dep, LRx non, respectively; Figure 4D). Figure 4 with 1 supplement see all Download asset Open asset LRx limited to deprived eye is sufficient to decrease ECM integrity in deprived V1b. (A) Representative triple labeled fluorescent micrographs of WFA-FITC staining (cyan), immunostaining for aggrecan (Agg; yellow) and parvalbumin (PV; magenta) of deprived (dep, contralateral to cMD, ipsilateral to eye patch) and non-deprived (non, ipsilateral to cMD, contralateral to eye patch) V1b after LRx to amblyopic eye. Roman numerals indicate cortical layer. WM = white matter. Inset: High magnification images of triple labeled PV+ interneurons (100X). (B) Fluorescence intensity profiles (mean ± SEM) along vertical depth of V1b. Dep LRx (dark red), non LRx (blue). (C) A significant decrease in WFA and Agg mean fluorescence intensity 250–400 μm from surface in dep V1b; n = 5; *p<0.05, Student’s T-test. (D) LRx-induced a significant decrease in WFA and Agg fluorescence intensity at PV+ and PV-locations in dep V1b; n (subjects, ROIs)=(5, 73 , 5 78), for LRx dep, LRx non, respectively; *p<0.05, Student’s T-test. Figure 4—source data 1 Source data for Figure 4. https://cdn.elifesciences.org/articles/52503/elife-52503-fig4-data1-v2.xlsx Download elife-52503-fig4-data1-v2.xlsx DE regulates threshold for perisynaptic MMP2/9 activation Our previous work demonstrated that MMP2/9 biomarker expression is low in the adult visual cortex, indicating that ambient light does not typically stimulate activatioin of this proteinase (Murase et al., 2017). The robust induction of MMP2/9 activity by reintroduction to ambient light, therefore, suggests that DE may lower the threshold for MMP2/9 activation. To test this prediction, we used two-photon live imaging of the MMP2/9 biomarker in awake binocular mice. In these experiments, visual deprivation must be maintained during i.c. delivery of the MMP2/9 biomarker and during two-photon imaging following DE. To achieve this, we designed a novel imaging chamber containing an aperture for the placement of the objective on the cranial imaging window without light exposure (Figure 5A). In addition, we employed a small peptide MMP2/9 biomarker (A580, Mw: 1769, Anaspec) that diffuses ~1 cm from the injection site, which allowed delivery at the cranial window margin. The biomarker is a synthetic substrate for MMP2/9, containing a C-terminal fluorescent donor carboxy-tetramethyl-rhodamine (TAMRA) and an N-terminal non-fluorescent acceptor QXL (quencher) for intramolecular FRET. In the absence of MMP2/9 activity intramolecular FRET (from TAMRA to QXL) quenches fluorescence emission following excitation at 547 nm. If the peptide is cleaved by MMP2/9, intramolecular FRET is interrupted. We cfirst onfirmed the fluorescence emission peak (Em max = 585 nm) following excitation at 545 nm (Figure 5B) in vitro, demonstrating that the biomarker reports the activation of recombinant MMP. In vivo 2P live imaging of biomarker was acquired simultaneously with GFP in pyramidal neurons following AAV-CAMKII-GFP delivery. Adult mice received DE for 10 d prior to 40 s of light stimulation (470 nm LED, 1 Hz flash). Dual imaging of biomarker and GFP revealed that both signals remained stable in the absence of visual stimulation (light intensity = 0 cd/m2). In contrast, stimulation with moderate intensity light (300 cd/m2; equivalent to luminance in the laboratory) induced an increase in raw fluorescence and biomarker ΔF/F of the biomarker, but not co-localized GFP (Figure 5C). Population data reveals a significant increase in biomarker fluorescence in DE subjects following moderate intensity light stimulation (repeated measure ANOVA, F(1, 22), p<0.001; n = 12 puncta from three subjects; *p<0.001, Tukey-Kramer post hoc test; Figure 5D). The change in biomarker fluorescence was similar to that observed following higher intensity light stimulation (150,000 cd/m2, equivalent to direct sunlight at noon; One-way ANOVA, F(2, 40)=6.3, p=0.0042, n = 12, 12, 19 puncta from three subjects each, for 0, 300, 150,000 cd/m2, respectively; Figure 5E). Importantly, moderate intensity light stimulation (300 cd/m2) was insufficient to induce an increase in biomarker fluorescence in control (0 hr DE) or dark-adapted (18 hr DE) subjects (Figure 5E). To confirm the specificity of the biomarker in reporting activity of MMP2/9, DE subjects were stimulated with high intensity light in the presence of a potent and specific inhibitor of MMP9 (Inhibitor I, CAS 1177749-58-4; IC50 = 5 nM). Co-delivery of MMP9 inhibitor (MMP9i, 5 nM 4 μl at 100 nl/min) with biomarker 24 hr prior to LRx inhibited the increase in biomarker fluorescence by high intensity light (n = 13 puncta from 3 subjects for 0 and 150,000 cd/m2; Student’s T-test; p=0.13). Together this demonstrates that DE lowers the threshold for light-induced MMP2/9 activation in the adult visual cortex. Figure 5 Download asset Open asset DE lowers the threshold for light-induced activation of MMP2/9. (A) Dark chamber with an imaging window allows maintenance of visual deprivation during two photon live imaging of MMP2/9 biomarker. Left drawing: Top view of a subject wearing a custom aluminum headpost (1 cm diameter) magnetically held to an o-ring in the blackout ceiling of the dark camber (inset; 3 mm diameter magnets APEX magnets; magnetic field generation around V1,<20 gauss). The headpost is secured to a stereotax. The cannula for biomarker delivery is adjacent to theimaging window margin. Right drawing: Side view of a subject in the dark chamber. The headpost is magnetically attached to the o-ring opening of the blackout ceiling (magnet locations, yellow arrows). (B) In vitro emission spectrum of MMP2/9 biomarker A580 (2 ng/ml) incubated with activated rat recombinant MMP9 (rrMMP9, 100 ng). (C) Inset: Experimental timeline. Adult (>P90) WT mice received AAV-CaMKII-GFP~2 weeks before 10 d of DE. Biomarker was delivered 24 hr before imaging. Subjects received 40 s of light stimulation (1 Hz flash of 470 nm LED at 0 or 300 cd/m2). Left: Representative images of GFP (green) and biomarker (MMP, magenta) signals in V1b 10 s prior or 40 s after light stimulation at 0 or 300 cd/m2 in a DE subject. Right: Time course of raw fluorescent intensities (pixel) and ΔF/F of MMP biomarker (top) and co-localized GFP (bottom) within the single ROI denoted by yellow circle, from 10 s before (−10) to 40 s after (+40) light stimulation of 0 or 300 cd/m2 in a DE subject. (D) Summary data: Time course of ΔF/F of MMP biomarker from −10 s to +40 s of light stimulation of 0 or 300 cd/m2 in DE subjects. ΔF/F of MMP biomarker was stable in absence of visual stimulation (0 cd/m2) and increased over time in response to 300 cd/m2 light stimulation (mean ± SEM; Repeated measure ANOVA, F(1, 22), *p<0.001; n = 12 puncta from three subjects each). (E) Biomarker ΔF/F +40 s relative to 0 s as a function of DE (0, hr, 18 hr or 10 d) and light intensity (0, 300, or 150,000 cd/m2). Moderate intensity light did not induce a change in biomarker fluorescence in the absence of DE (blue line, p=0.49, Student’s T-test; n = 11, 10 puncta for 0 and 300 cd/m2, respectively). Following 18 hr of dark adaptation, a significant increase in biomarker fluorescence